000			01470 a2200409 4500
005			20250517153451.0
264		0	_c20170815
008			201708s 0 0 eng d
022			_a1528-0020
024	7		_a10.1182/blood-2017-04-742288 _2doi
040			_aNLM _beng _cNLM
100	1		_aBose, Prithviraj
245	0	0	_aJAK2 inhibitors for myeloproliferative neoplasms: what is next? _h[electronic resource]
260			_bBlood _c07 2017
300			_a115-125 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aBridged-Ring Compounds _xtherapeutic use
650	0	4	_aGene Expression
650	0	4	_aHumans
650	0	4	_aJanus Kinase 1 _xantagonists & inhibitors
650	0	4	_aJanus Kinase 2 _xantagonists & inhibitors
650	0	4	_aMutation
650	0	4	_aNitriles
650	0	4	_aPatient Safety
650	0	4	_aPolycythemia Vera _xdrug therapy
650	0	4	_aPrimary Myelofibrosis _xdrug therapy
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aPyrazoles _xtherapeutic use
650	0	4	_aPyrimidines _xtherapeutic use
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aThrombocythemia, Essential _xdrug therapy
650	0	4	_aTreatment Outcome
700	1		_aVerstovsek, Srdan
773	0		_tBlood _gvol. 130 _gno. 2 _gp. 115-125
856	4	0	_uhttps://doi.org/10.1182/blood-2017-04-742288 _zAvailable from publisher's website
999			_c27169363 _d27169363